Latest & greatest articles for ipratropium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ipratropium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ipratropium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ipratropium

2. Salbutamol and ipratropium by inhaler is superior to nebulizer in children with severe acute asthma exacerbation: Randomized clinical trial. (Abstract)

Salbutamol and ipratropium by inhaler is superior to nebulizer in children with severe acute asthma exacerbation: Randomized clinical trial. In moderate-severe asthma exacerbation, salbutamol by inhaler (MDI) is superior to salbutamol delivered by nebulizer (NEB); however, to our knowledge, no studies in children with exclusively severe exacerbations were performed.To compare the efficacy of salbutamol and ipratropium bromide by MDI versus by NEB in severe asthma exacerbations.We performed (...) a clinical trial enrolling 103 children (2-14 years of age) with severe asthma exacerbations (defined by the Pulmonary Score ≥ 7) seen at the emergency room in Asuncion, Paraguay. One group received salbutamol and ipratropium (two puff every 10 min for 2 h and then every 30 min for 2 h more) by MDI with a valved-holding chamber and mask along with oxygen by a cannula separately (MDI-SIB); and the other received nebulization with oxygen (NEB-SIB) of salbutamol and ipratropium (1 every 20 min for 2 h

2019 Pediatric pulmonology Controlled trial quality: uncertain

3. [Comparison by double-blind study of the combination of an aerosol of salbutamol and ipratropium bromide and its individual effect in chronic bronchitis and bronchial asthma]. (Abstract)

[Comparison by double-blind study of the combination of an aerosol of salbutamol and ipratropium bromide and its individual effect in chronic bronchitis and bronchial asthma]. 6229844 1984 03 22 2013 11 21 0014-2565 171 4 1983 Nov 30 Revista clinica espanola Rev Clin Esp [Comparison by double-blind study of the combination of an aerosol of salbutamol and ipratropium bromide and its individual effect in chronic bronchitis and bronchial asthma]. 265-8 Baños Hidalgo P P Ramos Martos A A Cabrera (...) Moreno R R Luque Leal J J Palacios Giner A A spa Clinical Trial Comparative Study English Abstract Journal Article Randomized Controlled Trial Comparación en estudio doble ciego de la asociación de un aerosol de salbutamol y bromuro de ipratropio y de su efecto individual en bronquitis crónica y asma bronquial. Spain Rev Clin Esp 8608576 0014-2565 0 Aerosols 0 Atropine Derivatives GR88G0I6UL Ipratropium QF8SVZ843E Albuterol IM Aerosols Albuterol administration & dosage Asthma drug therapy Atropine

1984 Revista Clinica Espanola Controlled trial quality: uncertain

4. Ipratropium

Ipratropium Top results for ipratropium - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ipratropium The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

5. Nebulized terbutaline & ipratropium bromide vs terbutaline alone in acute exacerbation of COPD requiring noninvasive ventilation: a randomized double blind controlled trial (Abstract)

Nebulized terbutaline & ipratropium bromide vs terbutaline alone in acute exacerbation of COPD requiring noninvasive ventilation: a randomized double blind controlled trial Short-acting β2 -agonists are the mainstay of treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in the emergency department (ED). It is still unclear whether the addition of short-acting anticholinergics is clinically more effective care compared to treatment with β2 -agonists (...) alone in patients with hypercapnic AECOPD.The objective was to evaluate whether combining ipratropium bromide (IB) to terbutaline reduces hospital and intensive care unit (ICU) admission rates compared to terbutaline alone in AECOPD hypercapnic patients.In this double-blind controlled trial, patients who were admitted to the ED for AECOPD requiring noninvasive ventilation (NIV) were randomized to receive either 5 mg of nebulized terbutaline combined to 0.5 mg of IB (terbutaline/IB group, n = 115

2018 EvidenceUpdates

6. Nebulized Ipratropium for Asthma Attack

Nebulized Ipratropium for Asthma Attack Nebulized Ipratropium for Asthma Attack – TheNNTTheNNT Nebulized Ipratropium Given During an Asthma Attack 11 for prevented hospitalization In Summary, for those who received the ipratropium: Benefits in NNT 90.9% saw no benefit from adding ipraptropium during an asthma attack 9.1% were helped by preventing hospitalization 1 in 11 were helped (preventing hospitalization) Harms in NNT 0% were harmed by drug side effects None were harmed (serious side (...) effects) View As: NNT % Source: Efficacy Endpoints: Need for hospitalization Harm Endpoints: Medication side effects Narrative: Acute asthma exacerbation is responsible for an estimated 1.6 million emergency department visits and over 440,000 hospital admissions per year . The cornerstone of management remains aerosolized, short acting, β2-agonists and systemic corticosteroids . Anticholinergic agents such as ipratropium bromide, are effective bronchodilators, but comparative studies suggest

2012 theNNT

7. Drugs - Ipratropium Bromide (Atrovent)

Drugs - Ipratropium Bromide (Atrovent) Ipratropium Bromide (Atrovent) IPR Drugs October 2006 Page 1 of 1 Drugs PRESENTATION Nebules containing ipratropium bromide 250 micrograms in 1ml or 500 micrograms in 2ml. ACTIONS 1.Ipratropium bromide is an antimuscarinic bronchodilator drug. It may provide short term relief in acute asthma, but beta 2 agonists (such as salbutamol) generally work more quickly. Ipratropium should be considered in acute severe or life threatening asthma or in cases of acute (...) asthma or COPD which fail to improve with standard therapy (including salbutamol). 2. Ipratropium is considered of greater bene?t in: a. children suffering acute asthma. b. adults suffering with COPD. DOSAGE AND ADMINISTRATION CAUTIONS Ipratropium should be used with care in patients with: • glaucoma (protect the eyes from mist). • pregnancy and breastfeeding. INDICATIONS Acute severe or life threatening asthma (to be given concurrent with ?rst dose of salbutamol). Acute asthma unresponsive

2007 Joint Royal Colleges Ambulance Liaison Committee

8. Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. Full Text available with Trip Pro

Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. Many patients with asthma require frequent rescue medication for acute symptoms despite appropriate controller therapies. Thus, determining the most effective relief regimen is important in the management of more severe asthma. This study's objective was to evaluate whether ipratropium bromide/albuterol metered-dose inhaler (CVT-MDI) provides

2016 BMC pulmonary medicine Controlled trial quality: predicted high

9. Response to nebulized salbutamol versus combination with ipratropium bromide in children with acute severe asthma. (Abstract)

Response to nebulized salbutamol versus combination with ipratropium bromide in children with acute severe asthma. To compare the efficacy of nebulised salbutamol alone and in combination with ipratropium bromide in acute severe asthma in children.The randomised controlled trial was conducted at the National Institute of Child Health, Karachi, from October 2012 to March 2013, and comprised patients with acute severe asthma who were randomised into two equal groups. Group A patients received 3 (...) doses of nebulised salbutamol alone (0.03 ml/kg/dose) at 15-minute intervals and Group B received 3 similar doses of salbutamol along with ipratropium (250 ug/dose). Acute severe asthma was categorised as serve exacerbation (clinical score >10) and moderate (5-10 score) based on Bentur Modification. Efficacy was measured after 5minutes of the last dose by change in severity score from severe exacerbation (baseline) to low score. SPSS 10 was used for statistical analysis.There were two groups of 100

2016 JPMA. The Journal of the Pakistan Medical Association Controlled trial quality: uncertain

10. [Fenoterol, ipratropium bromide and their combination in bronchial asthma]. (Abstract)

[Fenoterol, ipratropium bromide and their combination in bronchial asthma]. 6234440 1984 07 31 2013 11 21 0025-7753 82 14 1984 Apr 14 Medicina clinica Med Clin (Barc) [Fenoterol, ipratropium bromide and their combination in bronchial asthma]. 617-20 Palenciano L L de Vega A A Escribano D D spa Clinical Trial English Abstract Journal Article Randomized Controlled Trial Fenoterol, bromuro de ipratropio y asociación de ambos en asma bronquial. Spain Med Clin (Barc) 0376377 0025-7753 0 Atropine (...) Derivatives 0 Drug Combinations 0 Ethanolamines 22M9P70OQ9 Fenoterol GR88G0I6UL Ipratropium IM Adolescent Adult Aged Asthma drug therapy Atropine Derivatives therapeutic use Double-Blind Method Drug Combinations Drug Evaluation Ethanolamines therapeutic use Female Fenoterol therapeutic use Humans Ipratropium therapeutic use Male Middle Aged Random Allocation 1984 4 14 1984 4 14 0 1 1984 4 14 0 0 ppublish 6234440

1984 Medicina clinica Controlled trial quality: uncertain

11. The efficacy of nebulized albuterol/ipratropium bromide versus albuterol alone in the prehospital treatment of suspected reactive airways disease. (Abstract)

The efficacy of nebulized albuterol/ipratropium bromide versus albuterol alone in the prehospital treatment of suspected reactive airways disease. Ipratropium bromide has demonstrated efficacy when added to albuterol for the treatment of reactive airways disease (RAD). Its prehospital use has not been explored.A before-and-after design was used. Prehospital and emergency department (ED) medical records were examined retrospectively six months before and six months after institution of a new (...) protocol, which allowed the addition of ipratropium bromide to all nebulized treatments with albuterol. Primary outcome measures included: changes in vital signs (heart rate, respiratory rate, oxygen saturation), clinical improvement as assessed by paramedics, and admission rates.A total of 371 patients were included (n = 192 albuterol alone, n = 179 ipratropium/albuterol). There was no statistically significant difference between groups with regard to the change in heart rate, respiratory rate

2005 Prehospital emergency care

12. Ipratropium Bromide (Atrovent)

Ipratropium Bromide (Atrovent) Ipratropium Bromide (Atrovent) IPR Drugs October 2006 Page 1 of 1 Drugs PRESENTATION Nebules containing ipratropium bromide 250 micrograms in 1ml or 500 micrograms in 2ml. ACTIONS 1.Ipratropium bromide is an antimuscarinic bronchodilator drug. It may provide short term relief in acute asthma, but beta 2 agonists (such as salbutamol) generally work more quickly. Ipratropium should be considered in acute severe or life threatening asthma or in cases of acute asthma (...) or COPD which fail to improve with standard therapy (including salbutamol). 2. Ipratropium is considered of greater bene?t in: a. children suffering acute asthma. b. adults suffering with COPD. DOSAGE AND ADMINISTRATION CAUTIONS Ipratropium should be used with care in patients with: • glaucoma (protect the eyes from mist). • pregnancy and breastfeeding. INDICATIONS Acute severe or life threatening asthma (to be given concurrent with ?rst dose of salbutamol). Acute asthma unresponsive to salbutamol

2006 Joint Royal Colleges Ambulance Liaison Committee

13. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD Full Text available with Trip Pro

Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD Gani R, Griffin J, Kelly S, Rutten-van Molken M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared the cost-effectiveness of tiotropium, ipratropium, and salmeterol, for the treatment of chronic obstructive pulmonary disease. The authors concluded that tiotropium was a cost-effective alternative to ipratropium and salmeterol, and switching patients from ipratropium and salmeterol to tiotropium led to considerable cost savings

2010 NHS Economic Evaluation Database.

14. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

15. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD

Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD Friedman M, Serby C W, Menjoge S S, Wilson J D, Hilleman D E, Witek T J Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Pharmaceutical technology: ipratropium combined with albuterol in a single inhalational canister (Combivent; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA). Type of intervention Treatment. Economic

1999 NHS Economic Evaluation Database.

16. Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness

Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could (...) -commercial purposes, provided that attribution is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 29 Aug 2012 CONTEXT

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

18. Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD

Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03480997 Recruitment Status : Completed First Posted : March 29, 2018 Last Update

2018 Clinical Trials

19. Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD. Full Text available with Trip Pro

Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD. The use of chlorofluorocarbons (CFCs) has contributed to the depletion of the stratospheric ozone layer resulting in serious health concerns. Ipratropium bromide/salbutamol sulphate CFC-pressurized metered-dose inhalers (IB/SAL-CFC pMDI) have been in widespread use for many years without any apparent ill consequences. This combination has now been

2016 International journal of chronic obstructive pulmonary disease Controlled trial quality: predicted high

20. A randomized, placebo-controlled, double-blind trial on the management of post-infective cough by inhaled ipratropium and salbutamol administered in combination. (Abstract)

A randomized, placebo-controlled, double-blind trial on the management of post-infective cough by inhaled ipratropium and salbutamol administered in combination. Post-viral cough is a type of cough originating from upper respiratory tract infections that persists after the infection is resolved. Although it was hypothesized that bronchodilators might have a role in the management of post-viral cough, a clear demonstration of their efficacy is missing. Therefore, we tested the efficacy (...) of a combination of a β-agonist and an anticholinergic agent in reducing post-viral cough with a randomized, double blind, placebo controlled clinical trial. Patients were treated for 10 days with either a nebulized combination of salbutamol 1.875 mg/0.5 mL and ipratropium bromide 0.375 mg/0.5 mL, or a placebo, and followed up for another 10 days. Daytime and nighttime cough severity and spirometry testing were assessed before starting treatment, after 10 and 20 days. Ninety-two patients were randomized

2014 Pulmonary Pharmacology & Therapeutics Controlled trial quality: predicted high